AMAG Pharmaceuticals, Inc. (AMAG) to Post Q1 2018 Earnings of ($0.80) Per Share, Leerink Swann Forecasts

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) – Equities research analysts at Leerink Swann increased their Q1 2018 EPS estimates for AMAG Pharmaceuticals in a report released on Monday. Leerink Swann analyst J. Schwartz now expects that the specialty pharmaceutical company will post earnings of ($0.80) per share for the quarter, up from their prior forecast of ($0.81). Leerink Swann has a “Market Perform” rating on the stock. Leerink Swann also issued estimates for AMAG Pharmaceuticals’ Q2 2018 earnings at ($0.68) EPS, Q3 2018 earnings at ($2.13) EPS, Q4 2018 earnings at ($2.40) EPS, FY2018 earnings at ($6.04) EPS and FY2019 earnings at ($2.77) EPS.

A number of other research analysts also recently commented on the company. Piper Jaffray Companies initiated coverage on AMAG Pharmaceuticals in a report on Monday, October 23rd. They set a “neutral” rating and a $18.00 target price on the stock. Zacks Investment Research downgraded AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 24th. ValuEngine raised AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, January 3rd. B. Riley started coverage on AMAG Pharmaceuticals in a report on Thursday, December 7th. They issued a “neutral” rating and a $16.00 price target on the stock. Finally, Janney Montgomery Scott reissued a “hold” rating on shares of AMAG Pharmaceuticals in a report on Monday, October 23rd. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and two have assigned a buy rating to the stock. AMAG Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $19.89.

AMAG Pharmaceuticals (NASDAQ:AMAG) opened at $12.30 on Thursday. The company has a current ratio of 1.59, a quick ratio of 1.48 and a debt-to-equity ratio of 0.94. AMAG Pharmaceuticals has a 1-year low of $11.93 and a 1-year high of $25.20. The company has a market capitalization of $456.33, a P/E ratio of -2.02 and a beta of 0.79.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Balter Liquid Alternatives LLC bought a new stake in shares of AMAG Pharmaceuticals in the 4th quarter worth approximately $120,000. Hartford Investment Management Co. acquired a new stake in AMAG Pharmaceuticals in the 3rd quarter valued at approximately $186,000. Cubist Systematic Strategies LLC acquired a new stake in AMAG Pharmaceuticals in the 3rd quarter valued at approximately $197,000. 361 Capital LLC acquired a new stake in AMAG Pharmaceuticals in the 3rd quarter valued at approximately $197,000. Finally, Aperio Group LLC acquired a new stake in AMAG Pharmaceuticals in the 3rd quarter valued at approximately $198,000.

COPYRIGHT VIOLATION WARNING: This article was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.com-unik.info/2018/02/09/amag-pharmaceuticals-inc-amag-to-post-q1-2018-earnings-of-0-80-per-share-leerink-swann-forecasts.html.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Earnings History and Estimates for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit